Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fat-Induced Insulin Resistance Dose Finding in Healthy Volunteers
NCT03479671Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2020
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Intralipid 10% (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Insulin Sensitivity (rate of glucose disposal) at 6 hours. Started Jan 2020; status: completed.
02
Drugs
Intralipid 10%
Beyond the preview
Go deeper on NCT03479671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03479671.